Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,096 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle Control Clear all
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris

NCT01974141
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone Gel, Dapsone Gel Vehicle
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
12 Years and older
Enrollment
2,102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Encino, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis

NCT02655679
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
VTP-38543, Vehicle with Transcutol®P, Vehicle without Transcutol®P
Drug · Other
Lead sponsor
Vitae Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
West Dundee, Illinois • Fort Gratiot, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01881113
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris

NCT02160678
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Vehicle, Tazarotene Cream, 0.1 %, Tazorac Cream, 0.1%
Drug
Lead sponsor
G & W Laboratories Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,741 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Arlington Hts., Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 2 Interventional Results available

A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis

NCT02682238
View directory record Official record
Conditions
Hyperhidrosis
Interventions
BBI-4000, 15%, Vehicle gel
Drug · Other
Lead sponsor
Botanix Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
5
States / cities
San Diego, California • Miami, Florida • Carmel, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 20, 2026, 3:49 AM EDT
Not listed Phase 2 Interventional

A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis

NCT06108024
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
SM-020 gel 1.0%, Vehicle gel
Drug
Lead sponsor
DermBiont, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Coral Gables, Florida • New Brighton, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 2 Interventional Results available

A Study of a New Drug Treatment for Acne

NCT01326780
View directory record Official record
Conditions
Acne Vulgaris
Interventions
1.2% JNJ 10229570-AAA, 2.4% JNJ 10229570-AAA, 3.6% JNJ 10229570-AAA, Vehicle control
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
San Diego, California • Colorado Springs, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 20, 2026, 3:49 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Skin Hydration in Persons With Acne After Dietary Supplementation With Botanical Antioxidants

NCT04534140
View directory record Official record
Conditions
Acne Vulgaris, Acne
Interventions
HBKB Capsule, HBKB Supplement Vehicle
Dietary Supplement · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 3 Interventional Results available

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2

NCT01737762
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
HP802-247, Vehicle
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
37
States / cities
Phoenix, Arizona • Carlsbad, California • Castro Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 2 Interventional

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

NCT01639846
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
RX-10045, Vehicle for RX-10045 arm
Drug
Lead sponsor
C.T. Development America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia

NCT05665387
View directory record Official record
Conditions
Presbyopia
Interventions
0.1% STN1013600 ophthalmic solution, 0.3% STN1013600 ophthalmic solution, Placebo
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
47 Years to 55 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Glendale, California • Newport Beach, California • Morrow, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 2 Interventional Results available

The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis

NCT05356793
View directory record Official record
Conditions
Acute Infectious Conjunctivitis (Disorder)
Interventions
SCH-1, Placebo
Drug
Lead sponsor
Sacsh
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jackson Heights, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 20, 2026, 3:49 AM EDT
Not listed Phase 2 Interventional

Study in Subjects With Moderate Atopic Dermatitis

NCT03859986
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
ALX-101 Gel Vehicle, ALX-101 Gel 5%
Drug
Lead sponsor
Ralexar Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Aventura, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Controlled Study to Assess the Efficacy and Safety of S-Ibuprofen Topical Gel 5% (AP0302) in the Treatment of DOMS

NCT03852459
View directory record Official record
Conditions
Pain, Acute
Interventions
S-Ibuprofen, Vehicle
Drug
Lead sponsor
Aponia Laboratories, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction

NCT05261386
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
CBT-008
Drug
Lead sponsor
Cloudbreak Therapeutics, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

NCT02819284
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
62
States / cities
Birmingham, Alabama • Chandler, Arizona • Jonesboro, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 2 Interventional Results available

PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

NCT01155362
View directory record Official record
Conditions
Crohn's Disease
Interventions
Human Placenta-Derived Cells PDA001 Intravenous Infusion, Vehicle Control
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Orange, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT04742283
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
41
States / cities
Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 20, 2026, 3:49 AM EDT
Terminated Phase 2 Interventional

Green Tea Extract in Treating Patients With Actinic Keratosis

NCT00005097
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
Polyphenon E and Placebo
Drug
Lead sponsor
Frank Meyskens
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of STP206 in Healthy Adult Subjects

NCT00922324
View directory record Official record
Conditions
Healthy
Interventions
STP206 or vehicle control
Drug
Lead sponsor
Leadiant Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice.

NCT00301327
View directory record Official record
Conditions
Head Lice
Interventions
Summers 5% L.A.
Drug
Lead sponsor
Summers Laboratories
Industry
Eligibility
6 Months and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Miami, Florida • Council Bluffs, Iowa • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 20, 2026, 3:49 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Teen Driving Translation Study (NIH)

NCT05696353
View directory record Official record
Conditions
Drive, Recidivism, Communication, Feedback, Psychological
Interventions
In-vehicle Device, Expert-Delivered Parent Communication Training, Peer-Delivered Parent Communication Training
Combination Product · Behavioral
Lead sponsor
Ginger Yang
Other
Eligibility
16 Years to 18 Years
Enrollment
588 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation

NCT02060903
View directory record Official record
Conditions
Head Lice Infestation
Interventions
Abametapir Lotion 0.74% w/w, Vehicle Lotion
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
6 Months and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Dinuba, California • Los Angeles, California • West Palm Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 20, 2026, 3:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A 6-Week Study to Evaluate the Photoallergic Potential of Diacerein 1% Ointment in Healthy Volunteers

NCT03473197
View directory record Official record
Conditions
Healthy
Interventions
Diacerein 1% ointment
Drug
Lead sponsor
Castle Creek Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 20, 2026, 3:49 AM EDT